{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Irinotecan&page=17", "query": { "intervention": "Irinotecan", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 921, "total_pages": 93, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Irinotecan&page=18&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Irinotecan&page=16&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T02:13:33.885Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03715933", "title": "Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ewing Sarcoma", "Colorectal Adenocarcinoma" ], "interventions": [ { "name": "INBRX-109", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Trifluridine + Tipiracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inhibrx Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "12 Years to 85 Years" }, "enrollment_count": 411, "start_date": "2018-10-08", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-10-21T02:13:33.885Z", "location_count": 24, "location_summary": "Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 20 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03715933" }, { "nct_id": "NCT05592626", "title": "A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Genital Neoplasm, Female", "Urogenital Neoplasms", "Lung Neoplasm", "Neoplasms by Site", "Papillomavirus Infection", "Epstein-Barr Virus Infections", "Carcinoma", "Neoplasms", "Vulvar Neoplasms", "Vulvar Diseases", "Abdominal Neoplasm", "NSCLC (Non-small Cell Lung Cancer)", "Colorectal Cancer" ], "interventions": [ { "name": "STAR0602", "type": "DRUG" }, { "name": "Irinotecan (Camptosar)", "type": "COMBINATION_PRODUCT" }, { "name": "Docetaxel (Taxotere)", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Marengo Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 366, "start_date": "2023-01-04", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-21T02:13:33.885Z", "location_count": 13, "location_summary": "Sacramento, California • Celebration, Florida • Miami, Florida + 10 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Celebration", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05592626" }, { "nct_id": "NCT01937715", "title": "A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Carcinoma" ], "interventions": [ { "name": "PF-05212384", "type": "DRUG" }, { "name": "FOLFIRI regimen", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "FOLFIRI", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2014-02", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2016-08-18", "last_synced_at": "2026-10-21T02:13:33.885Z", "location_count": 35, "location_summary": "Fullerton, California • Irvine, California • Los Angeles, California + 15 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01937715" }, { "nct_id": "NCT00039468", "title": "Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2002-03", "completion_date": "2008-02", "has_results": false, "last_update_posted_date": "2011-10-27", "last_synced_at": "2026-10-21T02:13:33.885Z", "location_count": 2, "location_summary": "Lebanon, New Hampshire • Columbus, Ohio", "locations": [ { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00039468" }, { "nct_id": "NCT00954876", "title": "Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "capecitabine and cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Translational Genomics Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2009-08", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2022-10-20", "last_synced_at": "2026-10-21T02:13:33.885Z", "location_count": 1, "location_summary": "Spokane, Washington", "locations": [ { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00954876" }, { "nct_id": "NCT06995872", "title": "Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "rhIL-15", "type": "DRUG" }, { "name": "Dinituximab", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "3 Years to 35 Years" }, "enrollment_count": 40, "start_date": "2025-10-21", "completion_date": "2029-06-01", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-21T02:13:33.885Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06995872" }, { "nct_id": "NCT00816777", "title": "Chemoembolization, Irinotecan Bead, Second Line Chemotherapy Treatment of Unresectable Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Unresectable Metastatic Colo-rectal Cancer" ], "interventions": [ { "name": "Chemoembolization with irinotecan Bead", "type": "PROCEDURE" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Generic Devices Consulting, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2008-12", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2018-09-07", "last_synced_at": "2026-10-21T02:13:33.885Z", "location_count": 3, "location_summary": "Aurora, Colorado • Chicago, Illinois • Burlington, Massachusetts", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Burlington", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00816777" }, { "nct_id": "NCT06028932", "title": "A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Carcinoma" ], "interventions": [ { "name": "Sacituzumab govitecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2024-01-08", "completion_date": "2027-11-01", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-10-21T02:13:33.885Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06028932" }, { "nct_id": "NCT00003134", "title": "Irinotecan in Treating Patients With Recurrent Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 64, "start_date": "1998-01", "completion_date": "2009-01", "has_results": false, "last_update_posted_date": "2016-12-07", "last_synced_at": "2026-10-21T02:13:33.885Z", "location_count": 19, "location_summary": "Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 16 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Cedar Rapids", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003134" }, { "nct_id": "NCT00813163", "title": "Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Neoplasms" ], "interventions": [ { "name": "PEP02", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PharmaEngine", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2009-01", "completion_date": "2012-07", "has_results": false, "last_update_posted_date": "2019-09-06", "last_synced_at": "2026-10-21T02:13:33.885Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00813163" } ] }